Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Etrumadenant - Arcus Biosciences

Drug Profile

Etrumadenant - Arcus Biosciences

Alternative Names: A2a/A2b adenosine receptor antagonist - Arcus Biosciences; AB 928; GS-0928

Latest Information Update: 09 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arcus Biosciences
  • Developer Arcus Biosciences; Genentech; Gilead Sciences; Memorial Sloan-Kettering Cancer Center; Washington University School of Medicine
  • Class Amines; Antineoplastics; Nitriles; Pyridines; Pyrimidines; Small molecules; Triazoles
  • Mechanism of Action Adenosine A2A receptor antagonists; Adenosine A2B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer; Liposarcoma; Non-small cell lung cancer; Pancreatic cancer; Rectal cancer
  • Phase I Cancer
  • No development reported Bladder cancer; Endometrial cancer; Gastrointestinal cancer; Head and neck cancer; Malignant melanoma; Merkel cell carcinoma; Oesophageal cancer; Ovarian cancer; Renal cancer; Triple negative breast cancer
  • Discontinued Prostate cancer

Most Recent Events

  • 02 Jun 2024 Efficacy and adverse events data from the phase Ib/II ARC-9 trial in Colorectal cancer released by Gilead Sciences
  • 05 Apr 2024 Interim adverse events and efficacy data from the phase-Ib/II MORPHEUS-PDAC trial in Pancreatic cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
  • 28 Dec 2023 No recent reports of development identified for phase-I development in Bladder-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top